NDAORALSYRUP
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KENACORT (triamcinolone diacetate) is an oral corticosteroid syrup approved in 1961 for inflammatory and allergic conditions. It works by suppressing immune-mediated inflammation through glucocorticoid receptor activation. The drug is administered orally as a liquid formulation, making it suitable for pediatric and patients requiring flexible dosing.
LOE Approaching
As an older corticosteroid approaching loss of exclusivity with moderate competitive pressure (30%), the team is likely focused on cost-containment and brand defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and approaching LOE, KENACORT represents a mature, maintenance-stage product offering limited career growth and advancement opportunities. Roles available are primarily focused on defending market share, managing generic competition, and operational efficiency rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on KENACORT at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.